Westside Investment Management Inc. Has $965,000 Stock Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Westside Investment Management Inc. decreased its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 13.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 54,996 shares of the company’s stock after selling 8,604 shares during the period. Westside Investment Management Inc.’s holdings in Pulse Biosciences were worth $965,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PLSE. Vanguard Group Inc. increased its position in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares during the last quarter. Creative Planning increased its holdings in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the 1st quarter valued at approximately $109,000. Price T Rowe Associates Inc. MD acquired a new stake in Pulse Biosciences in the 1st quarter worth approximately $88,000. Finally, Quest Partners LLC bought a new stake in Pulse Biosciences during the second quarter worth approximately $91,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Stock Up 3.6 %

PLSE opened at $17.27 on Thursday. Pulse Biosciences, Inc. has a 12-month low of $6.59 and a 12-month high of $22.69. The stock’s 50 day moving average price is $17.63 and its two-hundred day moving average price is $16.35.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the business posted ($0.19) EPS.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Wednesday, November 27th.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.